![]() Idelalisib structure | |
Clinical data | |
---|---|
Pronunciation | /aɪˈdɛləlɪsɪb/ eye-DEL-ə-li-sib |
Trade names | Zydelig |
Other names | GS-1101, CAL-101 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614040 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | >84%[5] |
Metabolism | Aldehyde oxidase (~70%), CYP3A4 (~30%);[6] UGT1A4 (minor) |
Metabolites | GS-563117 (inactive in vitro) |
Onset of action | Tmax = 1.5 hours |
Elimination half-life | 8.2 hours |
Excretion | Feces (78%), urine (14%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.235.089 |
Chemical and physical data | |
Formula | C22H18FN7O |
Molar mass | 415.432 g·mol−1 |
3D model (JSmol) | |
| |
|
Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers.[5][4] Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[7][8] It was developed by Gilead Sciences. It is taken orally (swallowed by mouth).
Spreitzer
was invoked but never defined (see the help page).Wu
was invoked but never defined (see the help page).